$XNCR

Montgomery Alan Bruce sold $62K of XNCR

Montgomery Alan Bruce sold 5,064 shares of Xencor Inc (XNCR) at $12.31 on 2026-06-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Montgomery Alan Bruce
Published Jun 17, 2026, 8:01 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 17, 2026, 8:03 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$XNCR
Neutral
high confidence
Mentioned
$XNCR
Relevance
2/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$XNCRNeutralLow
01

Why it matters

This disclosure updates the insider transaction record but does not introduce new company fundamentals (no earnings, guidance, trial, or deal information).

02

Market read

A director’s 10b5-1 sale is typically low-signal; any trading impact is usually limited unless corroborated by additional new disclosures.

03

What to watch

The article provides only the sale details; it does not state whether other insiders bought/sold around the same window or whether the company had concurrent news.

Relevance 2/10Novelty 3/10Timing: Filed 2026-06-17; sale executed 2026-06-15.

Background

The article is an SEC Form 4 disclosure of an insider transaction for Xencor, Inc.

Company-level read

Ticker impact

$XNCRNeutralHigh confidence
Context

Xencor director Montgomery Alan Bruce sold 5,064 shares in an open-market transaction on 2026-06-15 under a 10b5-1 plan.

Expected impact

Low near-term impact; any reaction likely fades quickly unless paired with other new fundamentals.

Evidence & confidence

The filing is a Form 4 insider sale with a pre-arranged 10b5-1 plan and no accompanying company-specific operational or financial catalyst in the text.

Market effects

No sector read-through; this is a single-company insider transaction with no new product/clinical/regulatory information.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can coincide with perceived valuation risk; traders may watch for follow-on sales or changes in buying behavior.

Key entities

  • Xencor, Inc.

    Issuer of the Form 4 insider transaction; director sold shares under a 10b5-1 plan.

  • Montgomery Alan Bruce

    Director who executed the open-market sale of 5,064 shares on 2026-06-15.

Related articles

$XNCRMed

Xencor Inc (XNCR): Results of Operations and Financial Condition

Xencor Inc (XNCR) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 xncr-20260805xexx991.htm EX-99.1 Document Exhibit 99.1 Xencor Reports Second Quarter 2026 Financial Results -- XmAb819 ccRCC expansion cohorts to be presented in an oral session at ESMO 2026; multiple Phase 1 sub-studies in earlier lines of therapy and additional indica

$CORTMed

Biotech Stocks At 52-Week Highs- CORT +30%, NEOG +22% & BAX +7% With Quarterly Results, TRAX, XNCR

The following biotech stocks reached 52-week highs on July 30, 2026, driven by key catalysts such as positive quarterly reports or announced settlement agreements. Corcept Therapeutics Incorporated (CORT) Corcept is a biopharmaceutical company engaged in developing medications for metabolic, oncologic, and neurologic diseases. Shares surged over 30% on Thursday to a 52-week high of $122.21.

$XNCRMedAI 8/10

Xencor, Inc.: Xencor to Receive $105 Million From Alexion to Resolve Ultomiris U.S. Royalty Matter

Xencor (NASDAQ:XNCR) said it reached a settlement with Alexion to resolve a U.S. Ultomiris (ravulizumab-cwvz) royalty dispute. Under the agreement, Xencor will receive $105 million in two $52.5 million payments, expected in Aug. 2026 and one year later. Alexion will owe no further U.S. royalties, while ex-U.S. royalties continue. Xencor expects cash through 2028.

$XNCRMed

Xencor Inc (XNCR): Results of Operations and Financial Condition

Xencor Inc (XNCR) filed an SEC Form 8-K — Results of Operations and Financial Condition. xncr-20260729 FALSE 0001326732 0001326732 2026-07-29 2026-07-29 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ___________________________________________________ FORM 8-K ___________________________________________________ CURRENT REPORT Pursuant to Sect